Pharmaceuticals

The Commission and the European Patent office are taking action to eradicate underhand tactics for keeping generic drugs off the market.

Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.

Drug companies have lost confidence in the UK as a place to do business, according to research by two leading industry bodies.

Follow the fashion: the biotech financing model has changed. But will today’s start-ups be tomorrow’s fashion victims?